Microplasmin and tissue plasminogen activator: Comparison of therapeutic effects in rat stroke model at multiparametric MR imaging

Radiology

Volumn 244, Issue 2, 2007, Pages 429-438

  Chen, Feng ^a,b   Suzuki, Yasuhiro ^c,d   Nagai, Nobuo ^c   Sun, Xihe ^a,e   Wang, Huaijun ^a   Yu, Jie ^a   Marchal, Guy ^a   Ni, Yicheng ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SOUTHEAST UNIVERSITY   (China)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d HAMAMATSU UNIVERSITY   (Japan)

^e WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GADODIAMIDE; MICROPLASMIN; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPARATUS; ARTICLE; BRAIN CORTEX; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN PERFUSION; CONTROLLED STUDY; DIFFUSION; DIFFUSION WEIGHTED IMAGING; DISEASE MODEL; DRUG EFFECT; FIBRINOLYTIC THERAPY; IMAGE ANALYSIS; MIDDLE CEREBRAL ARTERY; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NONHUMAN; PATIENT SELECTION; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; SCORING SYSTEM; SPRAGUE DAWLEY RAT; STROKE;

ANIMALS; CEREBROVASCULAR ACCIDENT; CHI-SQUARE DISTRIBUTION; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING; PEPTIDE FRAGMENTS; PLASMIN; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RATS; STATISTICS, NONPARAMETRIC; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34447526569     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2442061316     Document Type: Article

References (36)

1. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985;230:1289-1292.
2. Tatlisumak T, Li F. Use of diffusion- and perfusion-weighted magnetic resonance imaging in drug development for ischemic stroke. Curr Drug Targets CNS Neurol Disord 2003;2:131-141.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
4. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274: 1017-1025.
5. Dijkhuizen RM, Asahi M, Wu O, Rosen BR, Lo EH. Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke 2002;33:2100-2104.
6. Busch E, Kruger K, Fritze K, Allegrini PR, Hoehn-Berlage M, Hossmann KA. Bloodbrain harrier disturbances after rt-PA treatment of thromboembolic stroke in the rat. Acta Neurochir Suppl 1997;70:206-208.
7. Wang X, Tsuji K, Lee SR, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35:2726-2730.
8. Jiang Q, Zhang RL, Zhang ZG, et al. Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke. J Cereb Blood Flow Metab 2000;20:21-27.
9. Provenzale JM, Jahan R, Naidich TP, Fox AJ. Assessment of the patient with hyperacute stroke: imaging and therapy. Radiology 2003;229:347-359.
10. Niessen F, Hilger T, Hoehn M, Hossmann KA. Thrombolytic treatment of clot embolism in rat: comparison of intra-arterial and intravenous application of recombinant tissue plasminogen activator. Stroke 2002;33: 2999-3005.
11. Busch E, Beaulieu C, de Crespigny A, Kreischer S, Diener HC, Moseley ME. Combined X-ray angiography and diffusion-perfusion MRI for studying stroke evolution after rt-PA treatment in rats. Brain Res 2002;953:112-118.
12. Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs 2002;11:1623-1632.
13. Collen D. Revival of plasmin as a therapeutic agent? Thromb Haemost 2001;86:731-732.
14. Nagai N, Demarsin E, Van Hoef B, et al. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost 2003;1:307-313.
15. Suzuki Y, Chen F, Ni Y, Marchal G, Collen D, Nagai N. Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI. Stroke 2004;35:2402-2406.
16. Schlaug G, Benfield A, Baird AE, et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology 1999;53:1528-1537.
17. Fisher M, Ginsberg M. Current concepts of the ischemic penumbra: introduction. Stroke 2004;35:2657-2658.
18. Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 2003;34:575-583.
19. Chen F, Suzuki Y, Nagai N, et al. Visualization of stroke with clinical MR imagers in rats: a feasibility study. Radiology 2004;233: 905-911.
20. Chen F, Suzuki Y, Nagai N, et al. Rat cerebral ischemia induced with photochemical occlusion of proximal middle cerebral artery: a stroke model for MR imaging research. MAGMA 2004;17:103-108.
21. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987;58:1078-1084.
22. Chen F, Suzuki Y, Nagai N, Peeters R, Marchal G, Ni Y. Dynamic susceptibility contrast-enhanced perfusion MR imaging at 1.5 T predicts final infarct size in a rat stroke model. J Neurosci Methods 2005;141:55-60.
23. Suzuki Y, Nagai N, Collon D. Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice. J Thromb Haemost 2004;2: 1617-1621.
24. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986;17:472-476.
25. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 2002;33:2279-2284.
26. Kidwell CS, Alger JR, Saver JL. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 2003;34: 2729-2735.
27. Takamatsu H, Tatsumi M, Nitta S, et al. Time courses of progress to the chronic stage of middle cerebral artery occlusion models in rats. Exp Brain Res 2002;146:95-102.
28. Liebeskind DS. Collateral circulation. Stroke 2003;34:2279-2284.
29. Takamatsu H, Tsukada H, Kakiuchi T, Tatsumi M, Umemura K. Changes in local cerebral blood flow in photochemically induced thrombotic occlusion model in rats. Eur J Pharmacol 2000;398:375-379.
30. Kawai H, Umemura K, Nakashima M. Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn J Pharmacol 1995;69:143-148.
31. Takamatsu H, Kondo K, Ikeda Y, Umemura K. Hydroxyl radical generation after the third hour following ischemia contributes to brain damage. Eur J Pharmacol 1998;352: 165-169.
32. Takamatsu H, Kondo K, Ikeda Y, Umemura K. Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion. Eur J Pharmacol 1998;362:137-142.
33. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003;112: 1533-1540.
34. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003;9: 1313-1317.
35. d'Arcy JA, Collins DJ, Padhani AR, Walker-Samuel S, Suckling J, Leach MO. Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. RadioGraphics 2006;26:621-632.
36. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 2003;101: 3002-3007.